The study confirmed that MSI-1436 is a selective inhibitor of PTP-1B, and its central and peripheral effects provide promise for the simultaneous treatment of both type 2 diabetes and obesity.

Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 ...